Trial record 12 of 16 for:    LFB

Willebrand International Non-interventional Global Surveillance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01949220
Recruitment Status : Unknown
Verified March 2016 by Laboratoire français de Fractionnement et de Biotechnologies.
Recruitment status was:  Recruiting
First Posted : September 24, 2013
Last Update Posted : August 24, 2017
Information provided by (Responsible Party):
Laboratoire français de Fractionnement et de Biotechnologies

Brief Summary:
Collect information about WILLFACT or WILFACTIN in their real life clinical use and identify the therapeutic practices in an international environment.

Condition or disease
Von Willebrand Disease

Detailed Description:
Non-interventional, prospective, non comparative, international, multicentre study.

Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: International Post-Marketing Surveillance of Willfact-Wilfactin in Patients With Inherited Von Willebrand Disease.
Study Start Date : March 2014
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

Von Willebrand factor deficient patient
Inherited von Willebrand disease

Primary Outcome Measures :
  1. Documentation of product consumption data [ Time Frame: at each follow-up visit, up to 24 months ]
    Product consumption (VWF International Units) by analysis of posology, frequency in relation to the severity of bleeding, type of surgery and other clinical situations.

Secondary Outcome Measures :
  1. Collection and analysis of adverse events and VWF immunological safety [ Time Frame: at each follow-up visit, up to 24 months ]
    Adverse event (type, seriousness, severity, frequency, outcome), anti VWF-antibody and anti FVIII-antibody.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient, whatever their age, with inherited von Willebrand disease

Inclusion Criteria:

  • Patients with inherited von Willebrand disease
  • Patients treated with WILLFACT or WILFACTIN
  • Patient or parent/legal representative who has provided written signed and dated informed consent before any data collection.

Exclusion Criteria:

  • Patients who usually do not keep injection log up to date, when treated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01949220

Contact: LFB Biomedicaments +33 1 69827010

Hopital des enfants Reine Fabiola Recruiting
Antwerpen, Belgium
Principal Investigator: Van den akker Machiel, Dr.         
UZA hopital universitaire Recruiting
Edegem, Belgium, 2650
Principal Investigator: Maes Philip, Dr.         
University Hospital Recruiting
Brno, Czechia, 625 00
Principal Investigator: Blatný Jan, Dr.         
University Central Hospital Recruiting
Helsinki, Finland
Principal Investigator: Lassila Riitta, Dr.         
Charité Universitätsmedizin Recruiting
Berlin, Germany
Principal Investigator: Koscielny Jurgen, Dr         
GZRR Gerinnungszentrum Rhein/ Ruhr Recruiting
Duisburg, Germany
Principal Investigator: Halimeh Susan, Dr         
Universitatsklinikum Recruiting
Essen, Germany
Principal Investigator: Alexander Roth, Dr         
Goethe Universitat Recruiting
Frankfurt, Germany, 60590
Principal Investigator: Wolfgang MIESBACH, Dr         
Medizinische Hochschule Hannover Recruiting
Hannover, Germany
Principal Investigator: Wermes Cornelia, Dr         
Werlhof-Institut für Hämostaseologie GmbH Recruiting
Hannover, Germany
Principal Investigator: Von Depka Mario, Dr         
Universitätsklinikum Schleswig-Holstein Recruiting
Kiel, Germany
Principal Investigator: Nowak-Göttl Ulrike, Prof         
Universitatsklinikum Recruiting
Mainz, Germany
Principal Investigator: Charis Von Auer, Dr         
Klinikum der Universität Recruiting
München, Germany
Principal Investigator: Spannagl Michael, Prof         
Hemophilia center "LAIKO" general hospital Recruiting
Athens, Greece
Principal Investigator: Olga Katsarou-Fasouli, Dr         
Centro di Riferimento Regionale per Emofilia e Trombosi Recruiting
Catania, Italy
Principal Investigator: Cultrera Dorina, Dr.ssa         
AOUC- Azienda Ospedaliero-Universitaria Carregi Recruiting
Firenze, Italy
Principal Investigator: Silvia Linari, Dra         
University of Milan Recruiting
Milan, Italy, 20122
Principal Investigator: Flora PEYVANDI, Prof         
Oslo University Hospital Not yet recruiting
Oslo, Norway
Principal Investigator: Pal andre Holme, Pr         
Sponsors and Collaborators
Laboratoire français de Fractionnement et de Biotechnologies
Study Director: Wolfgang MIESBACH, Dr Medizinische Klinik III, Goethe Universitat, D-60590 Frankfurt/Main (Germany)
Study Director: Flora PEYVANDI, Prof. Faculty of Medicine, University of Milan, 20122 Milan (Italy)

Responsible Party: Laboratoire français de Fractionnement et de Biotechnologies Identifier: NCT01949220     History of Changes
Other Study ID Numbers: WINGS
First Posted: September 24, 2013    Key Record Dates
Last Update Posted: August 24, 2017
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Laboratoire français de Fractionnement et de Biotechnologies:
Von Willebrand disease
Von Willebrand factor

Additional relevant MeSH terms:
Von Willebrand Diseases
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Blood Platelet Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn